Eli Lilly (LLY) Q4 2024 Annual Earnings
LLY·Reported February 6, 2025·Before market open
Eli Lilly reported Q4 2024 revenue of $13.5B. Diluted EPS came in at $5.32, beat the $5.03 consensus by $0.29. Eli Lilly reports across 4 business segments, led by Cardiometabolic Health, Oncology, and Immunology.
Revenue
$13.5B
Diluted EPS
$5.32beat by $0.29
Consensus: $5.03
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Eli Lilly's Q4 2024 earnings report.
Eli Lilly (LLY) reported Q4 2024 earnings on February 6, 2025 before market open.
Eli Lilly reported revenue of $13.5B and diluted EPS of $5.32 for Q4 2024.
EPS beat the consensus estimate of $5.03 by $0.29.
You can read the 10-K periodic report (0000059478-25-000067) directly on SEC EDGAR. The filing index links above go to sec.gov.